193 related articles for article (PubMed ID: 24012867)
1. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
[TBL] [Abstract][Full Text] [Related]
2. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
3. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension.
Surwase SA; Itkonen L; Aaltonen J; Saville D; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Biopharm; 2015 Oct; 96():32-43. PubMed ID: 26092472
[TBL] [Abstract][Full Text] [Related]
4. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
5. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
6. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method.
Takeuchi H; Nagira S; Yamamoto H; Kawashima Y
Int J Pharm; 2005 Apr; 293(1-2):155-64. PubMed ID: 15778053
[TBL] [Abstract][Full Text] [Related]
7. Improved physical stability of amorphous state through acid base interactions.
Telang C; Mujumdar S; Mathew M
J Pharm Sci; 2009 Jun; 98(6):2149-59. PubMed ID: 18837038
[TBL] [Abstract][Full Text] [Related]
8. Effect of wet milling process on the solid state of indomethacin and simvastatin.
Sharma P; Denny WA; Garg S
Int J Pharm; 2009 Oct; 380(1-2):40-8. PubMed ID: 19576976
[TBL] [Abstract][Full Text] [Related]
9. Surface crystallization of indomethacin below Tg.
Wu T; Yu L
Pharm Res; 2006 Oct; 23(10):2350-5. PubMed ID: 16927184
[TBL] [Abstract][Full Text] [Related]
10. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
11. Effect of processing route on the surface properties of amorphous indomethacin measured by inverse gas chromatography.
Burnett DJ; Khoo J; Naderi M; Heng JY; Wang GD; Thielmann F
AAPS PharmSciTech; 2012 Dec; 13(4):1511-7. PubMed ID: 23135965
[TBL] [Abstract][Full Text] [Related]
12. Assessing the re-crystallization behaviour of amorphous lactose using the RH-perfusion cell.
Timmermann IL; Steckel H; Trunk M
Eur J Pharm Biopharm; 2006 Aug; 64(1):107-14. PubMed ID: 16527465
[TBL] [Abstract][Full Text] [Related]
13. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
14. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.
Crowley KJ; Zografi G
Pharm Res; 2003 Sep; 20(9):1417-22. PubMed ID: 14567636
[TBL] [Abstract][Full Text] [Related]
15. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
16. Crystallization Kinetics of Indomethacin/Polyethylene Glycol Dispersions Containing High Drug Loadings.
Duong TV; Van Humbeeck J; Van den Mooter G
Mol Pharm; 2015 Jul; 12(7):2493-504. PubMed ID: 26056715
[TBL] [Abstract][Full Text] [Related]
17. Spatial confinement can lead to increased stability of amorphous indomethacin.
Nielsen LH; Keller SS; Gordon KC; Boisen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):418-25. PubMed ID: 22521331
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.
Kaminska E; Adrjanowicz K; Zakowiecki D; Milanowski B; Tarnacka M; Hawelek L; Dulski M; Pilch J; Smolka W; Kaczmarczyk-Sedlak I; Kaminski K
Pharm Res; 2014 Oct; 31(10):2887-903. PubMed ID: 24831310
[TBL] [Abstract][Full Text] [Related]
19. Correlation of inhibitory effects of polymers on indomethacin precipitation in solution and amorphous solid crystallization based on molecular interaction.
Chauhan H; Kuldipkumar A; Barder T; Medek A; Gu CH; Atef E
Pharm Res; 2014 Feb; 31(2):500-15. PubMed ID: 24122167
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
Xiang TX; Anderson BD
J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
